DENVER, Colo., Dec 17, 2024 (247marketnews.com)- Tonix Pharmaceuticals (NASDAQ: TNXP) stated that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) filing for TNX-102 SL (cyclobenzaprine HCl sublingual tablets), a 5.6 mg, non-opioid, centrally-acting analgesic, for the management of fibromyalgia, which affects more than 10 million American adults, mostly women.
The FDA is expected to assign the NDA a Prescription Drug User Fee Act (PDUFA) target action date in a Day 74 Letter and confirm with Tonix if the FDA grants Priority Review.
Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, commented, “The FDA’s acceptance of our NDA represents another step forward as we pursue our goal of delivering the first member of a new class of medicines for the management of fibromyalgia, a condition affecting over 10 million adults in the U.S.
“The fibromyalgia community, comprised of patients and their families and support groups, has been waiting for a new drug for over 15 years. Analysis of insurance claims in the U.S., commissioned by Tonix, have shown that 18 months after diagnosis, fibromyalgia patients were more likely to be prescribed addictive opioids than all three of the FDA-approved drugs combined.
“We look forward to working closely with the FDA throughout the NDA review period with the goal of bringing TNX-102 SL to the market to address the significant unmet needs of the fibromyalgia community as quickly as possible. Furthermore, this is an important milestone as we advance our commercial preparations in anticipation of a potential approval in 2025 with an accomplished commercial leadership team already in place, supporting our marketed products Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.”
The post FDA Accepts Tonix’s TNX-102 SL NDA for Fibromyalgia appeared first on 24/7 MarketNews.
